XOMA Royalty Corporation (XOMA)
NASDAQ:XOMA
XOMA Stock Chart & Stats
$32.98
$0.08(0.31%)
At close: 4:00 PM EST
$32.98
$0.08(0.31%)
Day’s Range― - ―
52-Week Range$18.35 - $39.92
Previous CloseN/A
Volume8.24K
Average Volume (3M)53.64K
Market Cap
$392.65M
Enterprise Value$450.46M
Total Cash (Recent Filing)$82.91M
Total Debt (Recent Filing)$131.56M
Price to Earnings (P/E)15.1
Beta1.32
Next Earnings
Apr 30, 2026EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.26
Shares Outstanding11,905,652
10 Day Avg. Volume49,949
30 Day Avg. Volume53,642
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)4.60
Price to Sales (P/S)9.17
P/FCF Ratio166.54
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue8.64
Enterprise Value/Gross Profit9.16
Enterprise Value/Ebitda31.38
Forecast
1Y Price Target
$73.50Price Target Upside122.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.81
Revenue Forecast (FY)$63.71M
Bulls Say, Bears Say
Bulls Say
Cost Discipline And ProfitabilityAnalyst notes disciplined operating expense management that supports an emerging path to sustained profitability as royalty streams scale.
Partnership Expansion And AcquisitionsAnalyst highlights expansion of the Takeda partnership and continued strategic acquisitions as drivers that can broaden the company's partnered asset base and enhance future transactional and royalty opportunities.
Royalty Income GrowthAnalyst views XOMA's maturing royalty model as positioned to generate increasing royalty income from commercial and late‑stage partnered assets through expected milestone payments and future royalties.
Bears Say
Clinical Setback RiskAnalyst points out that Rezolute's ersodetug did not achieve statistically significant reductions in hypoglycemia events, increasing clinical and commercial uncertainty for that partnered program.
Regulatory UncertaintyAnalyst highlights that Gossamer's planned meeting with the FDA to discuss a path forward introduces regulatory uncertainty for the related partnered asset and could affect future milestones.
Revenue Timing VolatilityAnalyst warns that milestone payments from partnered programs can arrive unevenly, creating revenue volatility and making short‑term revenue less predictable.
XOMA Royalty Corporation News
XOMA FAQ
What was XOMA Royalty Corporation’s price range in the past 12 months?
XOMA Royalty Corporation lowest stock price was $18.35 and its highest was $39.92 in the past 12 months.
What is XOMA Royalty Corporation’s market cap?
XOMA Royalty Corporation’s market cap is $392.65M.
When is XOMA Royalty Corporation’s upcoming earnings report date?
XOMA Royalty Corporation’s upcoming earnings report date is Apr 30, 2026 which is in 23 days.
How were XOMA Royalty Corporation’s earnings last quarter?
XOMA Royalty Corporation released its earnings results on Mar 18, 2026. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of -$0.115 by $0.375.
Is XOMA Royalty Corporation overvalued?
According to Wall Street analysts XOMA Royalty Corporation’s price is currently Undervalued.
Does XOMA Royalty Corporation pay dividends?
XOMA Royalty Corporation does not currently pay dividends.
What is XOMA Royalty Corporation’s EPS estimate?
XOMA Royalty Corporation’s EPS estimate is 0.16.
How many shares outstanding does XOMA Royalty Corporation have?
XOMA Royalty Corporation has 11,905,652 shares outstanding.
What happened to XOMA Royalty Corporation’s price movement after its last earnings report?
XOMA Royalty Corporation reported an EPS of $0.26 in its last earnings report, beating expectations of -$0.115. Following the earnings report the stock price went up 1.296%.
Which hedge fund is a major shareholder of XOMA Royalty Corporation?
Currently, no hedge funds are holding shares in XOMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
XOMA Royalty Corporation Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$73.50 (122.86% Upside)
$73.50 (122.86% Upside)
Hedge Fund Trend
Increased
By 53.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 13.0%
Last 30 Days ▲ 13.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.28%
12-Months-Change
Fundamentals
Return on Equity
16.22%
Trailing 12-Months
Asset Growth
-8.15%
Trailing 12-Months
Company Description
XOMA Royalty Corporation
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
XOMA Company Deck
XOMA Earnings Call
Q4 2026
0:00 / 0:00
XOMA Stock 12 Month Forecast
Average Price Target
$73.50
▲(122.86% Upside)
Technical Analysis
Ocugen
―
Corvus Pharmaceuticals
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
15.87% Insiders
18.95% Mutual Funds
29.87% Other Institutional Investors
26.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---